You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Presentations largely reflected negatively on the utility of PD-L1 for stratifying response, but pivotal new data on tumor mutational burden as assessed by Foundation Medicine's genomic sequencing panel.
In developing the new tools, Google trained artificial intelligence algorithms to aid pathologists in making breast and prostate cancer diagnoses.
Participants shared data from head-to-head assay comparisons, reflected on the advancement of NGS and digital PCR methods, and discussed new standardization projects.
Representatives from industry, academia, the FDA, and insurance companies gathered for a joint FDA- and American Association for Cancer Research-sponsored workshop.